STRATA Skin Sciences to Report First Quarter 2025 Financial Results on May 14, 2025 and Provide Corporate Update
STRATA Skin Sciences (NASDAQ: SSKN), a medical technology company focused on dermatologic treatments, has scheduled its first quarter 2025 financial results announcement for May 14, 2025 after market close. The company will host a conference call at 5:00 p.m. ET the same day, featuring management remarks and a Q&A session.
Interested U.S. participants can join via phone at 1-866-524-3160 (domestic) or 1-412-317-6760 (international). A live webcast will also be available. The call replay will be accessible until May 21, 2025, through multiple channels including phone (1-877-344-7529 or 1-412-317-0088) with access code 6753445, and webcast replay available until September 21, 2025.
STRATA Skin Sciences (NASDAQ: SSKN), un'azienda di tecnologia medica specializzata in trattamenti dermatologici, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per il 14 maggio 2025 dopo la chiusura del mercato. La società terrà una conference call alle 17:00 ET dello stesso giorno, con interventi del management e una sessione di domande e risposte.
I partecipanti interessati negli Stati Uniti potranno collegarsi telefonicamente al numero 1-866-524-3160 (nazionale) o 1-412-317-6760 (internazionale). Sarà inoltre disponibile una diretta web. La registrazione della chiamata sarà accessibile fino al 21 maggio 2025 tramite vari canali, tra cui telefono (1-877-344-7529 o 1-412-317-0088) con codice di accesso 6753445, e la replica webcast sarà disponibile fino al 21 settembre 2025.
STRATA Skin Sciences (NASDAQ: SSKN), una empresa de tecnología médica enfocada en tratamientos dermatológicos, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el 14 de mayo de 2025 después del cierre del mercado. La compañía realizará una llamada conferencia a las 5:00 p.m. ET ese mismo día, con comentarios de la dirección y una sesión de preguntas y respuestas.
Los participantes interesados en EE. UU. pueden unirse por teléfono al 1-866-524-3160 (nacional) o 1-412-317-6760 (internacional). También habrá una transmisión en vivo disponible. La repetición de la llamada estará accesible hasta el 21 de mayo de 2025 a través de múltiples canales, incluyendo teléfono (1-877-344-7529 o 1-412-317-0088) con código de acceso 6753445, y la repetición del webcast estará disponible hasta el 21 de septiembre de 2025.
STRATA Skin Sciences (NASDAQ: SSKN)은 피부과 치료에 중점을 둔 의료 기술 회사로, 2025년 1분기 재무 실적 발표를 2025년 5월 14일 장 마감 후에 예정하고 있습니다. 회사는 같은 날 오후 5시(동부 시간)에 경영진 발언과 질의응답 세션이 포함된 컨퍼런스 콜을 진행할 예정입니다.
미국 내 관심 있는 참가자는 전화 1-866-524-3160(국내) 또는 1-412-317-6760(국제)로 참여할 수 있습니다. 라이브 웹캐스트도 제공됩니다. 콜 녹음은 2025년 5월 21일까지 여러 채널을 통해 이용 가능하며, 전화(1-877-344-7529 또는 1-412-317-0088)에서 액세스 코드 6753445를 입력하면 되고, 웹캐스트 녹화는 2025년 9월 21일까지 시청할 수 있습니다.
STRATA Skin Sciences (NASDAQ : SSKN), une entreprise de technologie médicale spécialisée dans les traitements dermatologiques, a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le 14 mai 2025 après la clôture du marché. La société tiendra une conférence téléphonique à 17h00 ET le même jour, comprenant des remarques de la direction et une session de questions-réponses.
Les participants intéressés aux États-Unis peuvent se joindre par téléphone au 1-866-524-3160 (domestique) ou au 1-412-317-6760 (international). Un webcast en direct sera également disponible. La rediffusion de l'appel sera accessible jusqu'au 21 mai 2025 via plusieurs canaux, y compris par téléphone (1-877-344-7529 ou 1-412-317-0088) avec le code d'accès 6753445, et la rediffusion du webcast sera disponible jusqu'au 21 septembre 2025.
STRATA Skin Sciences (NASDAQ: SSKN), ein Medizintechnologieunternehmen mit Schwerpunkt auf dermatologischen Behandlungen, hat die Veröffentlichung der Finanzergebnisse für das erste Quartal 2025 für den 14. Mai 2025 nach Börsenschluss angekündigt. Am selben Tag um 17:00 Uhr ET wird das Unternehmen eine Telefonkonferenz mit Managementkommentaren und einer Fragerunde abhalten.
Interessierte Teilnehmer aus den USA können telefonisch unter 1-866-524-3160 (national) oder 1-412-317-6760 (international) teilnehmen. Es wird auch ein Live-Webcast angeboten. Die Aufzeichnung des Anrufs ist bis zum 21. Mai 2025 über verschiedene Kanäle verfügbar, einschließlich Telefon (1-877-344-7529 oder 1-412-317-0088) mit Zugangscode 6753445, und die Webcast-Wiedergabe ist bis zum 21. September 2025 abrufbar.
- None.
- None.
HORSHAM, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report first quarter 2025 financial results on Wednesday, May 14, 2025 after the market close.
STRATA management will subsequently host a conference call at 5:00 p.m. ET on Wednesday, May 14, 2025 to review financial results and provide an update on corporate developments. Following management’s formal remarks, there will be a question-and-answer session.
To listen to the conference call, interested parties within the U.S. should dial 1-866-524-3160 (domestic) or 1-412-317-6760 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the STRATA Skin Sciences, Inc. conference call.
The conference call will also be available through a live webcast that can be accessed at STRATA Skin Sciences YE24 Earnings Webcast.
A telephonic replay of the call will be available until May 21, 2025 by dialing 1-877-344-7529 (or 1-412-317-0088 for international toll callers) and using replay access code 6753445. To access the replay using an international dial-in number, please see here.
A webcast earnings call replay will be available approximately one hour after the live call and remain accessible until September 21, 2025.
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClear®X Acne Therapy System.
STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.
Safe Harbor
This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to launch and sell products recently acquired or to be developed in the future, the Company’s ability to develop social media marketing campaigns, direct to consumer marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions labor supply shortages, or supply chain interruptions resulting from fiscal, political factors, international conflicts, responses, or conditions affecting the Company, the medical device industry and our customers and patients in general, as well as more specific risks and uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com.
Investor Contact:
CORE IR
516-222-2560
IR@strataskin.com
FAQ
When will STRATA Skin Sciences (SSKN) report Q1 2025 earnings?
How can I join STRATA Skin Sciences (SSKN) Q1 2025 earnings call?
Until when is SSKN's Q1 2025 earnings call replay available?
What is the replay access code for STRATA Skin Sciences Q1 2025 earnings call?
